Citations

Showing 10 of 108162 citations.

Sarcomas Arising in Paget Disease of Bone: A Clinicopathologic Analysis of 70 Cases
Deyrup, Andrea T., Montag, Anthony, Inwards, Carrie Y., Swee, Ronald G., Unni, K. Krishnan, Xu, Zhiheng

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 11, 2021 | Volume: 131 | Issue: 6 | Pages: 942-946

10.5858/2007-131-942-saipdo | PMID 17550323 Get It

Abstract Context. —Sarcomatous transformation is a rare complication of Paget disease of bone. Prognosis in patients with other types of sarcomas arising in bone has improved in the last several decades because of therapeutic advances. However, because of the rarity of Paget sarcoma, outcome studies in these patients are limited. Objective. —To determine whether prognosis for Paget sarcoma has improved. Design. —Seventy cases of sarcomas arising in the setting of Paget disease were collected, and the histologic and clinical findings were reviewed. Clinical follow-up was obtained in 67 cases. Results. —Sarcoma arising in Paget disease tended to arise in older men (46 men, 24 women; age range, 31–88 years; mean age, 66 years) and predominated in the axial skeleton (n = 37), especially in the pelvis. Thirty-three patients had a clinical history of Paget disease ranging in duration from 16 months to 30 years (mean, 15 years). No significant difference in incidence between monostotic (n = 33) and polyostotic (n = 36) disease was noted. Most tumors were osteosarcomas (88%). All tumors were high grade. Follow-up information was obtained in 67 of 70 cases (range of follow-up, 1–252 months). Survival ranged from 1 month to 20 years, with a 5-year survival rate of 10%. Conclusions. —Prognosis remains poor in patients with Paget sarcoma. There is no significant correlation between the number of bones involved with Paget disease or the duration of disease and development of Paget sarcoma. Poor prognosis in Paget sarcoma is unrelated to site or stage at presentation.
Type IV Collagen Immunostaining Is a Simple, Reliable Diagnostic Tool for Distinguishing Between Adenomatous and Normal Pituitary Glands
Lloyd, Ricardo V., McKeever, Paul E. , Jarzembowski, Jason A.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 11, 2021 | Volume: 131 | Issue: 6 | Pages: 931-935

10.5858/2007-131-931-ticiia | PMID 17550321 Get It

Abstract Context. —Pituitary adenomas are clinically diagnosed based on radiologic studies and/or secondary effects of hormone production. Definitive pathologic identification relies on immunohistochemical detection of a clonal population of hormone-producing cells. However, not all adenomas secrete hormones, so performing a battery of stains is inefficient. Reports have shown decreased type IV collagen in the stroma of other epithelial tumors. Objective. —To validate type IV collagen immunohistochemistry as a diagnostic method. Design. —We immunostained 27 adenomas and 19 normal pituitaries. The areas with the sparsest type IV collagen fibers were viewed at 3 magnifications (×10, ×20, and ×40 objectives), counting 1, 3, or 10 microscopic fields. A field was scored as “traversable” if a path existed from any point on the periphery of the field to a point on the approximately opposite periphery that did not cross any stained fibers. Results were compared with reticulin staining and to the existing diagnosis previously determined by histology, hormone immunostaining, and clinical correlation. Results. —Adenomas have less type IV collagen in their basement membranes, leading to sparser, trabecular staining in neoplasms versus a more rigid meshwork pattern in normal glands. One might envision the stained fibers as maze walls—one can traverse medium-powered fields in an adenoma, but one hits dead ends and gets trapped in those of a normal gland. Finding a single representative ×10 field to be traversable was 97.5% sensitive and 96.5% specific for an adenoma. Reticulin staining yielded identical results. Conclusions. —Type IV collagen immunostaining is a simple and reliable method of diagnosing pituitary adenomas.
Clinical Laboratory Reports in Molecular Pathology
Gulley, Margaret L. , Braziel, Rita M., Halling, Kevin C. , Kant, Jeffrey A., Nowak, Jan A. , Oliveira, André M. , Polesky, Herbert F., Silverman, Lawrence M., Tubbs, Raymond R., Deerlin, Vivianna M. Van, Vance, Gail H. , Versalovic, James , Hsi, Eric D. , Nikiforova, Marina N. , Ogino, Shuji , Deerlin, Vivianna M. Van

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 11, 2021 | Volume: 131 | Issue: 6 | Pages: 852-863

10.5858/2007-131-852-clrimp | PMID 17550311 Get It

Abstract Context. —Molecular pathology is a rapidly growing area of laboratory medicine in which DNA and RNA are analyzed. The recent introduction of array technology has added another layer of complexity involving massive parallel analysis of multiple genes, transcripts, or proteins. Objective. —As molecular technologies are increasingly implemented in clinical settings, it is important to bring uniformity to the way that test results are reported. Data Sources. —The College of American Pathologists Molecular Pathology Resource Committee members summarize elements that are already common to virtually all molecular pathology reports, as set forth in the College of American Pathologists checklists used in the laboratory accreditation process. Consensus recommendations are proposed to improve report format and content, and areas of controversy are discussed. Resources are cited that promote use of proper gene nomenclature and that describe methods for reporting mutations, translocations, microsatellite instability, and other genetic alterations related to inherited disease, cancer, identity testing, microbiology, and pharmacogenetics. Conclusions. —These resources and recommendations provide a framework for composing patient reports to convey molecular test results and their clinical significance to members of the health care team.
Systemic Mastocytosis: A Concise Clinical and Laboratory Review
Patnaik, Mrinal M. , Rindos, Michelle, Tefferi, Ayalew , Pardanani, Animesh , Kouides, Peter A.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 11, 2021 | Volume: 131 | Issue: 5 | Pages: 784-791

10.5858/2007-131-784-smacca | PMID 17488167 Get It

Abstract Context. —Systemic mastocytosis is characterized by abnormal growth and accumulation of neoplastic mast cells in various organs. The clinical presentation is varied and may include skin rash, symptoms related to release of mast cell mediators, and/or organopathy from involvement of bone, liver, spleen, bowel, or bone marrow. Objective. —To concisely review pathogenesis, disease classification, clinical features, diagnosis, and treatment of mast cell disorders. Data Sources. —Pertinent literature emerging during the last 20 years in the field of mast cell disorders. Conclusions. —The cornerstone of diagnosis is careful bone marrow histologic examination with appropriate immunohistochemical studies. Ancillary tests such as mast cell immunophenotyping, cytogenetic/molecular studies, and serum tryptase levels assist in confirming the diagnosis. Patients with cutaneous disease or with low systemic mast cell burden are generally managed symptomatically. In the patients requiring mast cell cytoreductive therapy, treatment decisions are increasingly being guided by results of molecular studies. Most patients carry the kit D816V mutation and are predicted to be resistant to imatinib mesylate (Gleevec) therapy. In contrast, patients carrying the FIP1L1-PDGFRA mutation achieve complete responses with low-dose imatinib therapy. Other therapeutic options include use of interferon-α, chemotherapy (2-chlorodeoxyadenosine), or novel small molecule tyrosine kinase inhibitors currently in clinical trials.
In Reply
Fletcher, Christopher D.�M. , Inwards, Carrie Y., Montag, Anthony, Qualman, Stephen J., Krausz, Thomas, Rubin, Brian P. , Peabody, Terrance D. , Rosenberg, Andrew E. , Weiss, Sharon Whelan

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 11, 2021 | Volume: 131 | Issue: 5 | Pages: 681-682

10.5858/2007-131-681-ir Get It

Perineurioma: A Distinctive and Underrecognized Peripheral Nerve Sheath Neoplasm
Ellinger, Fred, Oliveira, André M. , Macarenco, Ricardo

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 11, 2021 | Volume: 131 | Issue: 4 | Pages: 625-636

10.5858/2007-131-625-padaup | PMID 17425397 Get It

Abstract Context. —Perineuriomas are benign peripheral nerve sheath neoplasms composed of perineurial cells with characteristic immunohistochemical and ultrastructural features. They have been traditionally classified into two main types according to their location—intraneural and extraneural—and overlap histologically with many other tumors, which may be diagnostically challenging to general surgical pathologists. Objective. —To review the clinical, morphologic, immunohistochemical, ultrastructural, cytogenetic, and molecular genetic aspects of perineurioma, as well as to discuss its clinicopathologic variants and differential diagnosis. Data Sources. —English-language literature published between 1966 and 2005 was reviewed. Conclusions. —The correct identification of perineuriomas is important to avoid unnecessary overtreatment. The histologic diagnosis should be confirmed through immunohistochemical studies (including epithelial membrane antigen, S100 protein, and more recently described antibodies such as claudin-1 and GLUT1) or electron microscopy. Cytogenetic and molecular genetic studies are still of limited value for the diagnosis of perineuriomas but may play a fundamental role in excluding important differential diagnoses and also in helping elucidate the biology of these poorly known neoplasms.
Leadership and Management Training for Residents and Fellows: A Curriculum for Future Medical Directors
Hemmer, Patrick R., Karon, Brad S. , Hernandez, James S , Cuthbert, Carla, Fidler, Mary E., Tazelaar, Henry D. , Tazelaar, Henry D.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 11, 2021 | Volume: 131 | Issue: 4 | Pages: 610-614

10.5858/2007-131-610-lamtfr | PMID 17425393 Get It

Abstract Context. —Management of laboratories and pathology practices is increasingly complex. Residents and fellows in laboratory medicine and pathology need more structured curricula in leadership and management (L&M) training to function as medical and laboratory directors. Objective. —To define a curriculum that provides basic competency in L&M for residents and fellows in pathology. Design. —A year-long formal L&M course included didactic lectures, interactive sessions, case scenarios, team-building exercises, formal team presentations (capstone project), and precourse and postcourse assessment of L&M knowledge. The curriculum meets requirements of American College of Graduate Medical Education and supports goals for leadership training of the College of American Pathologists. Participants evaluated (5-point scale) the content and speakers of all sessions. Trainees were evaluated after considering postcourse examination results, quality of the capstone presentation, and a global assessment. Results. —The 5 non-capstone sessions received evaluation scores ranging from 4.4 (informatics) to 5 (L&M basics). Postcourse test scores showed significant improvement when compared with the pretest scores for the 2003– 2004 and 2004–2005 trainee cohorts. Conclusions. —Short-term results indicate that the course described improves trainee knowledge of L&M issues.
Selected Diagnostic Problems in Neoplastic Dermatopathology
DiCaudo, David J. , McCalmont, Timothy H. , Wick, Mark R.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 11, 2021 | Volume: 131 | Issue: 3 | Pages: 434-439

10.5858/2007-131-434-sdpind | PMID 17516745 Get It

Abstract Context.—Selected cutaneous neoplasms share features with benign counterparts or have subtle morphologic features that could be overlooked by the pathologist. Objective.—To present clues to the diagnosis of potentially deceptive malignancies, including desmoplastic malignant melanoma, nevoid malignant melanoma, subcutaneous lymphoma, metastatic breast carcinoma, and epithelioid sarcoma. Data Sources.—Published literature and personal experience. Conclusions.—Knowledge of commonly misdiagnosed cutaneous neoplasms will help the general surgical pathologist avoid these potential pitfalls in neoplastic dermatopathology.
Epithelioid Cell Clusters With an Extensive Lymphoid Background
Zarka, Matthew A.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 11, 2021 | Volume: 131 | Issue: 3 | Pages: 424-433

10.5858/2007-131-424-eccwae | PMID 17516744 Get It

Abstract Context.—Fine-needle aspiration of salivary gland lesions can be particularly challenging for pathologists. There are numerous neoplasms that occur in this area and several cytologic variations of each specific lesion. Objective.—To present and discuss a practical pattern recognition approach to fine-needle aspiration diagnosis, which includes categorizing lesions that share a certain overall cytologic architectural pattern, followed by identifying unique cellular characteristics that are specific to a certain lesion. An extensive discussion of one cytologic common pattern of salivary gland lesions, “epithelioid cell clusters with an extensive lymphoid background,” is presented. The pathologic entities that fall under this architectural pattern group are discussed, with an emphasis on neoplasms. Data Sources.—Published literature and personal experience. Conclusions.—A practical cytologic architectural pattern method can aid the pathologist in rendering a correct diagnosis when evaluating salivary gland lesions. One common pattern in salivary gland cytopathology is epithelioid cell clusters with an extensive lymphoid background. This pattern is often associated with Warthin tumor; however, other benign and malignant entities fall under this diagnostic group. Unique cytologic features separate these lesions into their respective diagnostic category.
Transbronchial Biopsy Interpretation in the Patient With Diffuse Parenchymal Lung Disease
Leslie, Kevin O., Gruden, James F. , Parish, James M., Scholand, Mary Beth

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 11, 2021 | Volume: 131 | Issue: 3 | Pages: 407-423

10.5858/2007-131-407-tbiitp | PMID 17516743 Get It

Abstract Context. —The most common lung tissue samples seen by pathologists worldwide are obtained with the flexible bronchoscope. Specimens taken for examination of diffuse or multifocal parenchymal lung abnormalities pose special challenges for the general surgical pathologist, and these challenges are often compounded by high clinical expectations for accurate and specific diagnosis. Objective. —To present and discuss the most common histopathologic patterns and diagnostic entities seen in transbronchial biopsy specimens in the setting of diffuse or multifocal lung disease. Specifically, acute lung injury, eosinophilic pneumonia, diffuse alveolar hemorrhage, chronic cellular infiltrates, organizing pneumonia, alveolar proteinosis, sarcoidosis, Wegener granulomatosis, intravenous drug abuse-related microangiopathy, Langerhans cell histiocytosis, and lymphangioleiomyomatosis are presented. Clinical and radiologic context is provided for the more specific diagnostic entities. Data Sources. —The published literature and experience from a consultation practice. Conclusions. —The transbronchial biopsy specimen can provide valuable information for clinical management in the setting of diffuse or multifocal lung disease. Computed tomographic scans are useful for selecting appropriate patients to undergo biopsy and in limiting the differential diagnosis. Knowledge of the clinical context, radiologic distribution of abnormalities, and histopathologic patterns is essential. With this information, the surgical pathologist can substantially influence the diagnostic workup and help guide the clinician to an accurate clinical/radiologic/pathologic diagnosis.